B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11

B. Riley Securities has maintained a 'Buy' rating on OptimizeRx (NASDAQ: OPRX) and increased the price target from $10 to $11, as stated by analyst Anderson Schock.